Loading…

MEN1 Deficiency‐Driven Activation of the β‐Catenin‐MGMT Axis Promotes Pancreatic Neuroendocrine Tumor Growth and Confers Temozolomide Resistance

O6‐methylguanine DNA methyltransferase (MGMT) removes alkyl adducts from the guanine O6 position (O6‐MG) and repairs DNA damage. High MGMT expression results in poor response to temozolomide (TMZ). However, the biological importance of MGMT and the mechanism underlying its high expression in pancrea...

Full description

Saved in:
Bibliographic Details
Published in:Advanced science 2024-09, Vol.11 (35), p.e2308417-n/a
Main Authors: Xu, Junfeng, Lou, Xin, Wang, Fei, Zhang, Wuhu, Xu, Xiaowu, Ye, Zeng, Zhuo, Qifeng, Wang, Yan, Jing, Desheng, Fan, Guixiong, Chen, Xuemin, Zhang, Yue, Zhou, Chenjie, Chen, Jie, Qin, Yi, Yu, Xianjun, Ji, Shunrong
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c4157-b4b4ed1704bda4eed24a2d163dc5c9502293eaa7a507d38e9bbf45523bee71b63
container_end_page n/a
container_issue 35
container_start_page e2308417
container_title Advanced science
container_volume 11
creator Xu, Junfeng
Lou, Xin
Wang, Fei
Zhang, Wuhu
Xu, Xiaowu
Ye, Zeng
Zhuo, Qifeng
Wang, Yan
Jing, Desheng
Fan, Guixiong
Chen, Xuemin
Zhang, Yue
Zhou, Chenjie
Chen, Jie
Qin, Yi
Yu, Xianjun
Ji, Shunrong
description O6‐methylguanine DNA methyltransferase (MGMT) removes alkyl adducts from the guanine O6 position (O6‐MG) and repairs DNA damage. High MGMT expression results in poor response to temozolomide (TMZ). However, the biological importance of MGMT and the mechanism underlying its high expression in pancreatic neuroendocrine tumors (PanNETs) remain elusive. Here, it is found that MGMT expression is highly elevated in PanNET tissues compared with paired normal tissues and negatively associated with progression‐free survival (PFS) time in patients with PanNETs. Knocking out MGMT inhibits cancer cell growth in vitro and in vivo. Ectopic MEN1 expression suppresses MGMT transcription in a manner that depends on β‐Catenin nuclear export and degradation. The Leucine 267 residue of MEN1 is crucial for regulating β‐Catenin‐MGMT axis activation and chemosensitivity to TMZ. Interference with β‐Catenin re‐sensitizes tumor cells to TMZ and significantly reduces the cytotoxic effects of high‐dose TMZ treatment, and MGMT overexpression counteracts the effects of β‐Catenin deficiency. This study reveals the biological importance of MGMT and a new mechanism by which MEN1 deficiency regulates its expression, thus providing a potential combinational strategy for treating patients with TMZ‐resistant PanNETs. Temozolomide (TMZ) is a first‐in‐class clinical chemotherapeutic drug for the treatment of advanced PanNETs via inducing DNA damage, while MGMT repairs DNA damage and disrupts the TMZ response. This study reveals that MEN1 deficiency induces activation of the β‐Catenin‐MGMT axis, and the restoration of MEN1 or the suppression of β‐Catenin re‐sensitizes PanNETs to TMZ.
doi_str_mv 10.1002/advs.202308417
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_b9de0dc9db3b4166a7eac67e8116e9ed</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_b9de0dc9db3b4166a7eac67e8116e9ed</doaj_id><sourcerecordid>3083681495</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4157-b4b4ed1704bda4eed24a2d163dc5c9502293eaa7a507d38e9bbf45523bee71b63</originalsourceid><addsrcrecordid>eNqFks1uEzEUhUcIRKvSLUtkiQ2bBHvs-fEKRUkJlZqCILC1_HOncTVjt_ZMSljxCOx4Dx6Eh-BJcEiJWjasfOR77qd77ZNlTwkeE4zzl9Ks4zjHOcU1I9WD7DAnvB7RmrGHd_RBdhzjJcaYFLRipH6cHVCOk-DkMPu-ODknaAaN1Rac3vz6-m0W7BocmujermVvvUO-Qf0K0M8fqTqVPTjrklrMF0s0-Wwjehd853tIQjodIDVpdA5D8OCM18E6QMuh8wHNg7_pV0g6g6beNRAiWkLnv_jWd9YAeg_Rxj5B4En2qJFthOPb8yj7-PpkOX0zOns7P51OzkaakaIaKaYYGFJhpoxkACZnMjekpEYXmhc4zzkFKStZ4MrQGrhSDSuKnCqAiqiSHmWnO67x8lJcBdvJsBFeWvHnwocLIUPapwWhuAFsNDeKKkbKUlYgdVlBTUgJHExivdqxrgbVgdHg-iDbe9D7FWdX4sKvBSEsL3K2nebFLSH46wFiLzobNbStdOCHKNJH07ImjBfJ-vwf66UfgktvJSjBvGQ1Jji5xjuXDj7GAM1-GoLFNkNimyGxz1BqeHZ3h739b2KSge0MN7aFzX9wYjL79IHjuqK_Ab3i2Q4</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3109648010</pqid></control><display><type>article</type><title>MEN1 Deficiency‐Driven Activation of the β‐Catenin‐MGMT Axis Promotes Pancreatic Neuroendocrine Tumor Growth and Confers Temozolomide Resistance</title><source>Open Access: PubMed Central</source><source>Open Access: Wiley-Blackwell Open Access Journals</source><source>Publicly Available Content Database</source><creator>Xu, Junfeng ; Lou, Xin ; Wang, Fei ; Zhang, Wuhu ; Xu, Xiaowu ; Ye, Zeng ; Zhuo, Qifeng ; Wang, Yan ; Jing, Desheng ; Fan, Guixiong ; Chen, Xuemin ; Zhang, Yue ; Zhou, Chenjie ; Chen, Jie ; Qin, Yi ; Yu, Xianjun ; Ji, Shunrong</creator><creatorcontrib>Xu, Junfeng ; Lou, Xin ; Wang, Fei ; Zhang, Wuhu ; Xu, Xiaowu ; Ye, Zeng ; Zhuo, Qifeng ; Wang, Yan ; Jing, Desheng ; Fan, Guixiong ; Chen, Xuemin ; Zhang, Yue ; Zhou, Chenjie ; Chen, Jie ; Qin, Yi ; Yu, Xianjun ; Ji, Shunrong</creatorcontrib><description>O6‐methylguanine DNA methyltransferase (MGMT) removes alkyl adducts from the guanine O6 position (O6‐MG) and repairs DNA damage. High MGMT expression results in poor response to temozolomide (TMZ). However, the biological importance of MGMT and the mechanism underlying its high expression in pancreatic neuroendocrine tumors (PanNETs) remain elusive. Here, it is found that MGMT expression is highly elevated in PanNET tissues compared with paired normal tissues and negatively associated with progression‐free survival (PFS) time in patients with PanNETs. Knocking out MGMT inhibits cancer cell growth in vitro and in vivo. Ectopic MEN1 expression suppresses MGMT transcription in a manner that depends on β‐Catenin nuclear export and degradation. The Leucine 267 residue of MEN1 is crucial for regulating β‐Catenin‐MGMT axis activation and chemosensitivity to TMZ. Interference with β‐Catenin re‐sensitizes tumor cells to TMZ and significantly reduces the cytotoxic effects of high‐dose TMZ treatment, and MGMT overexpression counteracts the effects of β‐Catenin deficiency. This study reveals the biological importance of MGMT and a new mechanism by which MEN1 deficiency regulates its expression, thus providing a potential combinational strategy for treating patients with TMZ‐resistant PanNETs. Temozolomide (TMZ) is a first‐in‐class clinical chemotherapeutic drug for the treatment of advanced PanNETs via inducing DNA damage, while MGMT repairs DNA damage and disrupts the TMZ response. This study reveals that MEN1 deficiency induces activation of the β‐Catenin‐MGMT axis, and the restoration of MEN1 or the suppression of β‐Catenin re‐sensitizes PanNETs to TMZ.</description><identifier>ISSN: 2198-3844</identifier><identifier>EISSN: 2198-3844</identifier><identifier>DOI: 10.1002/advs.202308417</identifier><identifier>PMID: 39041891</identifier><language>eng</language><publisher>Germany: John Wiley &amp; Sons, Inc</publisher><subject>Animals ; Antineoplastic Agents, Alkylating - pharmacology ; Apoptosis ; beta Catenin - genetics ; beta Catenin - metabolism ; Brain cancer ; Cell cycle ; Cell growth ; Cell Line, Tumor ; Disease Models, Animal ; DNA damage ; DNA methylation ; DNA Modification Methylases - genetics ; DNA Modification Methylases - metabolism ; DNA Repair Enzymes - genetics ; DNA Repair Enzymes - metabolism ; Drug Resistance, Neoplasm - drug effects ; Drug Resistance, Neoplasm - genetics ; Female ; Humans ; Kinases ; Lymphatic system ; Male ; Medical prognosis ; MEN1 ; Metastasis ; MGMT ; Mice ; Mice, Nude ; Mutation ; Neuroendocrine tumors ; Neuroendocrine Tumors - drug therapy ; Neuroendocrine Tumors - genetics ; Neuroendocrine Tumors - metabolism ; Pancreas ; Pancreatic Neoplasms - drug therapy ; Pancreatic Neoplasms - genetics ; Pancreatic Neoplasms - metabolism ; Pancreatic Neoplasms - pathology ; Pancreatic neuroendocrine tumors ; Patients ; Proteins ; Proto-Oncogene Proteins - genetics ; Proto-Oncogene Proteins - metabolism ; Survival analysis ; temozolomide ; Temozolomide - pharmacology ; Transcription factors ; Tumor Suppressor Proteins - genetics ; Tumor Suppressor Proteins - metabolism</subject><ispartof>Advanced science, 2024-09, Vol.11 (35), p.e2308417-n/a</ispartof><rights>2024 The Author(s). Advanced Science published by Wiley‐VCH GmbH</rights><rights>2024 The Author(s). Advanced Science published by Wiley‐VCH GmbH.</rights><rights>2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the "License"). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c4157-b4b4ed1704bda4eed24a2d163dc5c9502293eaa7a507d38e9bbf45523bee71b63</cites><orcidid>0009-0002-0899-4874</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/3109648010/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/3109648010?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,11561,25752,27923,27924,37011,37012,44589,46051,46475,53790,53792,74897</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39041891$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Xu, Junfeng</creatorcontrib><creatorcontrib>Lou, Xin</creatorcontrib><creatorcontrib>Wang, Fei</creatorcontrib><creatorcontrib>Zhang, Wuhu</creatorcontrib><creatorcontrib>Xu, Xiaowu</creatorcontrib><creatorcontrib>Ye, Zeng</creatorcontrib><creatorcontrib>Zhuo, Qifeng</creatorcontrib><creatorcontrib>Wang, Yan</creatorcontrib><creatorcontrib>Jing, Desheng</creatorcontrib><creatorcontrib>Fan, Guixiong</creatorcontrib><creatorcontrib>Chen, Xuemin</creatorcontrib><creatorcontrib>Zhang, Yue</creatorcontrib><creatorcontrib>Zhou, Chenjie</creatorcontrib><creatorcontrib>Chen, Jie</creatorcontrib><creatorcontrib>Qin, Yi</creatorcontrib><creatorcontrib>Yu, Xianjun</creatorcontrib><creatorcontrib>Ji, Shunrong</creatorcontrib><title>MEN1 Deficiency‐Driven Activation of the β‐Catenin‐MGMT Axis Promotes Pancreatic Neuroendocrine Tumor Growth and Confers Temozolomide Resistance</title><title>Advanced science</title><addtitle>Adv Sci (Weinh)</addtitle><description>O6‐methylguanine DNA methyltransferase (MGMT) removes alkyl adducts from the guanine O6 position (O6‐MG) and repairs DNA damage. High MGMT expression results in poor response to temozolomide (TMZ). However, the biological importance of MGMT and the mechanism underlying its high expression in pancreatic neuroendocrine tumors (PanNETs) remain elusive. Here, it is found that MGMT expression is highly elevated in PanNET tissues compared with paired normal tissues and negatively associated with progression‐free survival (PFS) time in patients with PanNETs. Knocking out MGMT inhibits cancer cell growth in vitro and in vivo. Ectopic MEN1 expression suppresses MGMT transcription in a manner that depends on β‐Catenin nuclear export and degradation. The Leucine 267 residue of MEN1 is crucial for regulating β‐Catenin‐MGMT axis activation and chemosensitivity to TMZ. Interference with β‐Catenin re‐sensitizes tumor cells to TMZ and significantly reduces the cytotoxic effects of high‐dose TMZ treatment, and MGMT overexpression counteracts the effects of β‐Catenin deficiency. This study reveals the biological importance of MGMT and a new mechanism by which MEN1 deficiency regulates its expression, thus providing a potential combinational strategy for treating patients with TMZ‐resistant PanNETs. Temozolomide (TMZ) is a first‐in‐class clinical chemotherapeutic drug for the treatment of advanced PanNETs via inducing DNA damage, while MGMT repairs DNA damage and disrupts the TMZ response. This study reveals that MEN1 deficiency induces activation of the β‐Catenin‐MGMT axis, and the restoration of MEN1 or the suppression of β‐Catenin re‐sensitizes PanNETs to TMZ.</description><subject>Animals</subject><subject>Antineoplastic Agents, Alkylating - pharmacology</subject><subject>Apoptosis</subject><subject>beta Catenin - genetics</subject><subject>beta Catenin - metabolism</subject><subject>Brain cancer</subject><subject>Cell cycle</subject><subject>Cell growth</subject><subject>Cell Line, Tumor</subject><subject>Disease Models, Animal</subject><subject>DNA damage</subject><subject>DNA methylation</subject><subject>DNA Modification Methylases - genetics</subject><subject>DNA Modification Methylases - metabolism</subject><subject>DNA Repair Enzymes - genetics</subject><subject>DNA Repair Enzymes - metabolism</subject><subject>Drug Resistance, Neoplasm - drug effects</subject><subject>Drug Resistance, Neoplasm - genetics</subject><subject>Female</subject><subject>Humans</subject><subject>Kinases</subject><subject>Lymphatic system</subject><subject>Male</subject><subject>Medical prognosis</subject><subject>MEN1</subject><subject>Metastasis</subject><subject>MGMT</subject><subject>Mice</subject><subject>Mice, Nude</subject><subject>Mutation</subject><subject>Neuroendocrine tumors</subject><subject>Neuroendocrine Tumors - drug therapy</subject><subject>Neuroendocrine Tumors - genetics</subject><subject>Neuroendocrine Tumors - metabolism</subject><subject>Pancreas</subject><subject>Pancreatic Neoplasms - drug therapy</subject><subject>Pancreatic Neoplasms - genetics</subject><subject>Pancreatic Neoplasms - metabolism</subject><subject>Pancreatic Neoplasms - pathology</subject><subject>Pancreatic neuroendocrine tumors</subject><subject>Patients</subject><subject>Proteins</subject><subject>Proto-Oncogene Proteins - genetics</subject><subject>Proto-Oncogene Proteins - metabolism</subject><subject>Survival analysis</subject><subject>temozolomide</subject><subject>Temozolomide - pharmacology</subject><subject>Transcription factors</subject><subject>Tumor Suppressor Proteins - genetics</subject><subject>Tumor Suppressor Proteins - metabolism</subject><issn>2198-3844</issn><issn>2198-3844</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNqFks1uEzEUhUcIRKvSLUtkiQ2bBHvs-fEKRUkJlZqCILC1_HOncTVjt_ZMSljxCOx4Dx6Eh-BJcEiJWjasfOR77qd77ZNlTwkeE4zzl9Ks4zjHOcU1I9WD7DAnvB7RmrGHd_RBdhzjJcaYFLRipH6cHVCOk-DkMPu-ODknaAaN1Rac3vz6-m0W7BocmujermVvvUO-Qf0K0M8fqTqVPTjrklrMF0s0-Wwjehd853tIQjodIDVpdA5D8OCM18E6QMuh8wHNg7_pV0g6g6beNRAiWkLnv_jWd9YAeg_Rxj5B4En2qJFthOPb8yj7-PpkOX0zOns7P51OzkaakaIaKaYYGFJhpoxkACZnMjekpEYXmhc4zzkFKStZ4MrQGrhSDSuKnCqAiqiSHmWnO67x8lJcBdvJsBFeWvHnwocLIUPapwWhuAFsNDeKKkbKUlYgdVlBTUgJHExivdqxrgbVgdHg-iDbe9D7FWdX4sKvBSEsL3K2nebFLSH46wFiLzobNbStdOCHKNJH07ImjBfJ-vwf66UfgktvJSjBvGQ1Jji5xjuXDj7GAM1-GoLFNkNimyGxz1BqeHZ3h739b2KSge0MN7aFzX9wYjL79IHjuqK_Ab3i2Q4</recordid><startdate>20240901</startdate><enddate>20240901</enddate><creator>Xu, Junfeng</creator><creator>Lou, Xin</creator><creator>Wang, Fei</creator><creator>Zhang, Wuhu</creator><creator>Xu, Xiaowu</creator><creator>Ye, Zeng</creator><creator>Zhuo, Qifeng</creator><creator>Wang, Yan</creator><creator>Jing, Desheng</creator><creator>Fan, Guixiong</creator><creator>Chen, Xuemin</creator><creator>Zhang, Yue</creator><creator>Zhou, Chenjie</creator><creator>Chen, Jie</creator><creator>Qin, Yi</creator><creator>Yu, Xianjun</creator><creator>Ji, Shunrong</creator><general>John Wiley &amp; Sons, Inc</general><general>John Wiley and Sons Inc</general><general>Wiley</general><scope>24P</scope><scope>WIN</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7XB</scope><scope>88I</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>M2O</scope><scope>M2P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0009-0002-0899-4874</orcidid></search><sort><creationdate>20240901</creationdate><title>MEN1 Deficiency‐Driven Activation of the β‐Catenin‐MGMT Axis Promotes Pancreatic Neuroendocrine Tumor Growth and Confers Temozolomide Resistance</title><author>Xu, Junfeng ; Lou, Xin ; Wang, Fei ; Zhang, Wuhu ; Xu, Xiaowu ; Ye, Zeng ; Zhuo, Qifeng ; Wang, Yan ; Jing, Desheng ; Fan, Guixiong ; Chen, Xuemin ; Zhang, Yue ; Zhou, Chenjie ; Chen, Jie ; Qin, Yi ; Yu, Xianjun ; Ji, Shunrong</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4157-b4b4ed1704bda4eed24a2d163dc5c9502293eaa7a507d38e9bbf45523bee71b63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Animals</topic><topic>Antineoplastic Agents, Alkylating - pharmacology</topic><topic>Apoptosis</topic><topic>beta Catenin - genetics</topic><topic>beta Catenin - metabolism</topic><topic>Brain cancer</topic><topic>Cell cycle</topic><topic>Cell growth</topic><topic>Cell Line, Tumor</topic><topic>Disease Models, Animal</topic><topic>DNA damage</topic><topic>DNA methylation</topic><topic>DNA Modification Methylases - genetics</topic><topic>DNA Modification Methylases - metabolism</topic><topic>DNA Repair Enzymes - genetics</topic><topic>DNA Repair Enzymes - metabolism</topic><topic>Drug Resistance, Neoplasm - drug effects</topic><topic>Drug Resistance, Neoplasm - genetics</topic><topic>Female</topic><topic>Humans</topic><topic>Kinases</topic><topic>Lymphatic system</topic><topic>Male</topic><topic>Medical prognosis</topic><topic>MEN1</topic><topic>Metastasis</topic><topic>MGMT</topic><topic>Mice</topic><topic>Mice, Nude</topic><topic>Mutation</topic><topic>Neuroendocrine tumors</topic><topic>Neuroendocrine Tumors - drug therapy</topic><topic>Neuroendocrine Tumors - genetics</topic><topic>Neuroendocrine Tumors - metabolism</topic><topic>Pancreas</topic><topic>Pancreatic Neoplasms - drug therapy</topic><topic>Pancreatic Neoplasms - genetics</topic><topic>Pancreatic Neoplasms - metabolism</topic><topic>Pancreatic Neoplasms - pathology</topic><topic>Pancreatic neuroendocrine tumors</topic><topic>Patients</topic><topic>Proteins</topic><topic>Proto-Oncogene Proteins - genetics</topic><topic>Proto-Oncogene Proteins - metabolism</topic><topic>Survival analysis</topic><topic>temozolomide</topic><topic>Temozolomide - pharmacology</topic><topic>Transcription factors</topic><topic>Tumor Suppressor Proteins - genetics</topic><topic>Tumor Suppressor Proteins - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Xu, Junfeng</creatorcontrib><creatorcontrib>Lou, Xin</creatorcontrib><creatorcontrib>Wang, Fei</creatorcontrib><creatorcontrib>Zhang, Wuhu</creatorcontrib><creatorcontrib>Xu, Xiaowu</creatorcontrib><creatorcontrib>Ye, Zeng</creatorcontrib><creatorcontrib>Zhuo, Qifeng</creatorcontrib><creatorcontrib>Wang, Yan</creatorcontrib><creatorcontrib>Jing, Desheng</creatorcontrib><creatorcontrib>Fan, Guixiong</creatorcontrib><creatorcontrib>Chen, Xuemin</creatorcontrib><creatorcontrib>Zhang, Yue</creatorcontrib><creatorcontrib>Zhou, Chenjie</creatorcontrib><creatorcontrib>Chen, Jie</creatorcontrib><creatorcontrib>Qin, Yi</creatorcontrib><creatorcontrib>Yu, Xianjun</creatorcontrib><creatorcontrib>Ji, Shunrong</creatorcontrib><collection>Open Access: Wiley-Blackwell Open Access Journals</collection><collection>Wiley Online Library Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Open Access: DOAJ - Directory of Open Access Journals</collection><jtitle>Advanced science</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Xu, Junfeng</au><au>Lou, Xin</au><au>Wang, Fei</au><au>Zhang, Wuhu</au><au>Xu, Xiaowu</au><au>Ye, Zeng</au><au>Zhuo, Qifeng</au><au>Wang, Yan</au><au>Jing, Desheng</au><au>Fan, Guixiong</au><au>Chen, Xuemin</au><au>Zhang, Yue</au><au>Zhou, Chenjie</au><au>Chen, Jie</au><au>Qin, Yi</au><au>Yu, Xianjun</au><au>Ji, Shunrong</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>MEN1 Deficiency‐Driven Activation of the β‐Catenin‐MGMT Axis Promotes Pancreatic Neuroendocrine Tumor Growth and Confers Temozolomide Resistance</atitle><jtitle>Advanced science</jtitle><addtitle>Adv Sci (Weinh)</addtitle><date>2024-09-01</date><risdate>2024</risdate><volume>11</volume><issue>35</issue><spage>e2308417</spage><epage>n/a</epage><pages>e2308417-n/a</pages><issn>2198-3844</issn><eissn>2198-3844</eissn><abstract>O6‐methylguanine DNA methyltransferase (MGMT) removes alkyl adducts from the guanine O6 position (O6‐MG) and repairs DNA damage. High MGMT expression results in poor response to temozolomide (TMZ). However, the biological importance of MGMT and the mechanism underlying its high expression in pancreatic neuroendocrine tumors (PanNETs) remain elusive. Here, it is found that MGMT expression is highly elevated in PanNET tissues compared with paired normal tissues and negatively associated with progression‐free survival (PFS) time in patients with PanNETs. Knocking out MGMT inhibits cancer cell growth in vitro and in vivo. Ectopic MEN1 expression suppresses MGMT transcription in a manner that depends on β‐Catenin nuclear export and degradation. The Leucine 267 residue of MEN1 is crucial for regulating β‐Catenin‐MGMT axis activation and chemosensitivity to TMZ. Interference with β‐Catenin re‐sensitizes tumor cells to TMZ and significantly reduces the cytotoxic effects of high‐dose TMZ treatment, and MGMT overexpression counteracts the effects of β‐Catenin deficiency. This study reveals the biological importance of MGMT and a new mechanism by which MEN1 deficiency regulates its expression, thus providing a potential combinational strategy for treating patients with TMZ‐resistant PanNETs. Temozolomide (TMZ) is a first‐in‐class clinical chemotherapeutic drug for the treatment of advanced PanNETs via inducing DNA damage, while MGMT repairs DNA damage and disrupts the TMZ response. This study reveals that MEN1 deficiency induces activation of the β‐Catenin‐MGMT axis, and the restoration of MEN1 or the suppression of β‐Catenin re‐sensitizes PanNETs to TMZ.</abstract><cop>Germany</cop><pub>John Wiley &amp; Sons, Inc</pub><pmid>39041891</pmid><doi>10.1002/advs.202308417</doi><tpages>21</tpages><orcidid>https://orcid.org/0009-0002-0899-4874</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2198-3844
ispartof Advanced science, 2024-09, Vol.11 (35), p.e2308417-n/a
issn 2198-3844
2198-3844
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_b9de0dc9db3b4166a7eac67e8116e9ed
source Open Access: PubMed Central; Open Access: Wiley-Blackwell Open Access Journals; Publicly Available Content Database
subjects Animals
Antineoplastic Agents, Alkylating - pharmacology
Apoptosis
beta Catenin - genetics
beta Catenin - metabolism
Brain cancer
Cell cycle
Cell growth
Cell Line, Tumor
Disease Models, Animal
DNA damage
DNA methylation
DNA Modification Methylases - genetics
DNA Modification Methylases - metabolism
DNA Repair Enzymes - genetics
DNA Repair Enzymes - metabolism
Drug Resistance, Neoplasm - drug effects
Drug Resistance, Neoplasm - genetics
Female
Humans
Kinases
Lymphatic system
Male
Medical prognosis
MEN1
Metastasis
MGMT
Mice
Mice, Nude
Mutation
Neuroendocrine tumors
Neuroendocrine Tumors - drug therapy
Neuroendocrine Tumors - genetics
Neuroendocrine Tumors - metabolism
Pancreas
Pancreatic Neoplasms - drug therapy
Pancreatic Neoplasms - genetics
Pancreatic Neoplasms - metabolism
Pancreatic Neoplasms - pathology
Pancreatic neuroendocrine tumors
Patients
Proteins
Proto-Oncogene Proteins - genetics
Proto-Oncogene Proteins - metabolism
Survival analysis
temozolomide
Temozolomide - pharmacology
Transcription factors
Tumor Suppressor Proteins - genetics
Tumor Suppressor Proteins - metabolism
title MEN1 Deficiency‐Driven Activation of the β‐Catenin‐MGMT Axis Promotes Pancreatic Neuroendocrine Tumor Growth and Confers Temozolomide Resistance
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T23%3A13%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=MEN1%20Deficiency%E2%80%90Driven%20Activation%20of%20the%20%CE%B2%E2%80%90Catenin%E2%80%90MGMT%20Axis%20Promotes%20Pancreatic%20Neuroendocrine%20Tumor%20Growth%20and%20Confers%20Temozolomide%20Resistance&rft.jtitle=Advanced%20science&rft.au=Xu,%20Junfeng&rft.date=2024-09-01&rft.volume=11&rft.issue=35&rft.spage=e2308417&rft.epage=n/a&rft.pages=e2308417-n/a&rft.issn=2198-3844&rft.eissn=2198-3844&rft_id=info:doi/10.1002/advs.202308417&rft_dat=%3Cproquest_doaj_%3E3083681495%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4157-b4b4ed1704bda4eed24a2d163dc5c9502293eaa7a507d38e9bbf45523bee71b63%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3109648010&rft_id=info:pmid/39041891&rfr_iscdi=true